Key takeaways
- U.S. News & World Report released its inaugural ratings of the 11 best GLP-1 telehealth platforms to guide patients safely through virtual weight-loss care.
- Amazon One Medical topped the overall rankings with a 4.8 out of 5 score and won top honors for insurance support.
- Found ranked second overall at 4.6 and took first place in clinical support due to its robust physician oversight and patient check-ins.
- The rankings excluded platforms that exclusively sell compounded GLP-1s, focusing instead on providers prescribing FDA-approved brand-name drugs.
What happened
U.S. News & World Report has released its first-ever official ratings of the best telehealth platforms for GLP-1 weight-loss medications. Released on August 12, the new 2026–2027 rankings evaluate online providers on a five-point scale, giving consumers a structured way to compare digital clinics in a rapidly expanding and often confusing market.
Why it matters
With roughly 11% of American adults now taking a GLP-1 medication for weight loss, virtual prescribing has become a major pillar of obesity care. A recent KFF poll revealed that 17% of GLP-1 patients obtain their prescriptions through online telehealth providers rather than traditional in-person clinics.
While virtual care offers unmatched convenience and expands access for those with limited time or geographic barriers, medical experts have raised alarm bells regarding the quality of care. A July research letter published in JAMA by Yale University experts warned that some direct-to-consumer platforms prioritize rapid prescriptions over comprehensive, personalized medical oversight. By evaluating platforms on safety, support, and transparency, these new ratings aim to help US consumers separate high-quality clinical programs from predatory "prescription mills."
What the data says
To establish the rankings, U.S. News & World Report analyzed 20 telehealth companies. The publication restricted its evaluation to platforms that offer access to brand-name, FDA-approved GLP-1 medications like Wegovy and Zepbound. Platforms that exclusively sell compounded alternatives were excluded from the rankings because compounded formulations do not undergo the same FDA safety and quality review processes as brand-name drugs.
The evaluation combined internal research with a survey of 1,251 US adults who had utilized an online GLP-1 provider within the past year. Providers were scored on six critical metrics:
- Clinical support
- Screening rigor
- Transparency
- Insurance assistance
- Supplemental care
- Customer satisfaction
Out of the 20 evaluated companies, 11 earned top marks. The highest-rated GLP-1 telehealth platforms according to the report include:
- Amazon One Medical: 4.8 / 5
- Found: 4.6 / 5
- Mochi Health: 4.4 / 5
- Ro: 4.4 / 5
- Noom: 4.3 / 5
- PlushCare: 4.1 / 5
- Fridays: 4.0 / 5
- Ivim Health: 4.0 / 5
- LifeMD: 4.0 / 5
- Remedy Meds: 3.9 / 5
- WeightWatchers: 3.9 / 5
The publication also recognized individual standouts in specific operational areas. Found earned the highest score for clinical support (4.9 out of 5), which measures the availability of video visits, mandatory baseline lab work, follow-up response times, and active side-effect management. Meanwhile, Amazon One Medical claimed the top spot for insurance support (4.9 out of 5) for its navigation and prior authorization assistance.
How it compares
The telehealth landscape is highly fragmented, with monthly costs ranging from under $50 to more than $150 just for program access, excluding the price of the medication itself.
U.S. News & World Report's top-rated platform, Amazon One Medical, represents a traditional primary care model integrated with virtual services. PlushCare operates similarly, utilizing insurance-compatible virtual primary care visits. In contrast, specialized subscription programs like Found, Ro, and Noom bundle clinical care, coaching, and automated insurance prior-authorization support into a single monthly fee.
The decision by U.S. News to exclude compounding-only platforms highlights a massive dividing line in the industry. While brand-name GLP-1s can cost upwards of $1,000 to $1,350 per month out-of-pocket without insurance, compounded semaglutide and tirzepatide are frequently advertised online for $200 to $400 per month. By focusing exclusively on FDA-approved brands, these ratings prioritize clinical validation, but they leave out the low-cost compounding options that many cash-paying patients rely on to bypass shortages and high insurance copays.
How this fits the bigger picture
The rise of dedicated GLP-1 telehealth ratings underscores how permanent virtual obesity care has become in the United States. High demand has consistently outpaced supply, leading to historic manufacturer revenues. As discussed in our coverage of Eli Lilly's surging Zepbound and Mounjaro sales, the financial stakes in the weight-loss market are astronomical, driving a flood of new virtual startups to compete for patients.
This competition has forced major tech and retail giants to pivot. For example, Amazon’s high placement in these ratings is no coincidence; the e-commerce giant has aggressively targeted this space. As we noted when Amazon Pharmacy began offering weight-loss drugs under the Medicare Bridge Program, the company is positioning itself as a primary portal for both clinical prescribing and low-cost digital pharmacy delivery.
For patients, choosing a highly rated platform with strong clinical oversight is vital. Poor medical screening in virtual settings can lead to serious health complications, ranging from severe gastrointestinal issues to systemic complications. Patients can learn more about managing these risks by exploring our guide to GLP-1 side effects or by comparing specific drug profiles, such as semaglutide vs. tirzepatide, before booking a virtual consultation.
What happens next
This inaugural rating system is expected to push telehealth providers to elevate their clinical standards, particularly around screening and lab work. As the FDA continues to monitor drug shortages, the legal and regulatory landscape for compounded medications remains highly volatile. Telehealth platforms that rely heavily on compounding are likely to face increased pressure to build robust, brand-name insurance support programs.
In the coming months, clinical trials will continue to expand the medical use cases for these therapies beyond weight loss. Furthermore, public and private insurance policies will keep evolving, directly impacting how telehealth platforms help patients secure coverage.
Disclaimer: CompareRx does not provide medical advice. Always consult a qualified healthcare professional before starting or changing any medication or weight-loss program.